Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:95-100, 2006
DOI: 10.2337/diacare.29.01.06.dc05-0955
© 2006 by the American Diabetes Association
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scognamiglio, R.
Right arrow Articles by Avogaro, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scognamiglio, R.
Right arrow Articles by Avogaro, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Pathophysiology/Complications
Original Article

Effects of Different Insulin Regimes on Postprandial Myocardial Perfusion Defects in Type 2 Diabetic Patients

Roldano Scognamiglio, MD, Christian Negut, MD, Saula Vigili de Kreutzenberg, MD, Antonio Tiengo, MD and Angelo Avogaro, MD

Metabolic Cardiology, Division of Metabolic Diseases, Department of Clinical and Experimental Medicine, University of Padova Medical School, Padua, Italy

Address correspondence and reprint requests to Roldano Scognamiglio, MD, Cardiologia Metabolica, Divisione di Malattie del Metabolismo, Policlinico Universitario, via Giustiniani 2, 35128 Padova, Italy. E-mail address: r.scognamiglio{at}unipd.it


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
OBJECTIVE—Postprandial glycemia is an independent risk factor for cardiovascular disease that is more powerful than fasting glycemia and determines myocardial perfusion defects in type 2 diabetes. We examined the efficacy of two different insulin regimes (regular insulin and insulin analog) in controlling postprandial hyperglycemia and in preventing myocardial perfusion abnormalities.

RESEARCH DESIGN AND METHODS—A total of 20 consecutive type 2 diabetic patients and 20 control subjects were enrolled in this randomized, three-way, cross-over, placebo-controlled study. Myocardial perfusion was assessed by myocardial contrast echocardiography (MCE) in fasting and postprandial (120 min) state.

RESULTS—Insulin analog was associated with lower, but not statistically significant, postprandial glycemia than regular insulin (glucose increase: 116 ± 8 vs. 136 ± 5%, P = NS). However, the area under the curve following insulin analog was significantly lower than regular insulin (18,354 ± 702 vs. 20,757 ± 738 mg per 120 min, P = 0.032). Fasting myocardial flow velocity (ß), myocardial blood volume (MBV), and myocardial blood flow (MBF) did not differ between control and type 2 diabetic subjects. Postprandial ß (0.67 ± 0.24 vs. 0.92 ± 0.25, P < 0.01), MBV (8.4 ± 2 vs. 10.9 ± 1.2, P < 0.01), and MBF (5.6 ± 2 vs. 9.9 ± 2.8, P < 0.01) increased significantly in control subjects. In type 2 diabetes, during placebo in the postprandial state, ß increased (0.65 ± 0.27 vs. 0.89 ± 0.24, P < 0.01), while MBV (8.34 ± 1.2 vs. 4.3 ± 1.3, P < 0.01) and MBF (5.4 ± 1.5 vs. 3.4 ± 0.9, P < 0.01) decreased. Similar changes in MCE variables were observed after regular insulin: ß increased (0.65 ± 0.22 vs. 0.92 ± 0.12, P < 0.01) and MBV (8.2 ± 2 vs. 5.2 ± 1.16, P < 0.01) and MBF (5.4 ± 1.9 vs. 4.2 ± 0.86, P < 0.01) were reduced. After insulin analog, postprandial ß (0.66 ± 0.18 vs. 0.9 ± 0.18, P < 0.01), MBV (8.2 ± 1.6 vs. 9.6 ± 1.2, P < 0.01), and MBF (5.4 ± 2 vs. 7.2 ± 1.9, P < 0.01) increased. Values of postprandial MBV and MBF were higher after insulin analog than regular insulin treatment.

CONCLUSIONS—Insulin analog partially reversed myocardial perfusion abnormalities observed in postprandial state by improving glucose control.

Abbreviations: AUC, area under the curve • CVD, cardiovascular disesase • FFA, free fatty acid • MBF, myocardial blood flow • MBV, myocardial blood volume • MCE, myocardial contrast echocardiography


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
Diabetes is associated with a markedly increased risk of cardiovascular disease (CVD), and this excess risk is not explained by the increase of conventional cardiovascular risk factors (1). Several studies confirmed that tight glycemic control reduces and delays late diabetes and microvascular complications (2, 3). Considerable data indicate that postprandial plasma glucose level might be an independent risk factor of CVD that is more powerful than fasting hyperglycemia, and the presence of postprandial hyperglycemia is a significant predictor of myocardial infarction and death (4). Recently, the Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe (DECODE) study confirmed that postload hyperglycemia increases mortality and that postload glucose is a better predictor of mortality than fasting glucose (5). Postprandial hyperglycemia could result in labile nonenzymatic glycation, promotion of thrombosis, and production of free radicals that could generate tissue damage and favor the development of micro- and macrovascular complications (6). In a recent study including type 2 diabetic patients, postprandial hyperglycemia determined myocardial perfusion defects secondary to deterioration in microvascular function (7). Thus, clinically it seems reasonable to avoid excessive postprandial hyperglycemia in the management of diabetes (8).

The present study was conducted to compare the efficacy of two different insulin regimes (regular insulin or insulin analog) in controlling postprandial hyperglycemia and preventing myocardial perfusion defects in type 2 diabetic patients.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
RESULTS
 CONCLUSIONS
 References
 
Among type 2 diabetic patients regularly attending the Diabetes Clinic of University of Padua, we enrolled 20 consecutive patients with a diagnosis of type 2 diabetes for ≥6 months but ≤10 years, aged ≤60 years, with a BMI of 26.4 ± 1.4 and HbA1c (A1C) of 7.2 ± 1%. All patients were managed by dietary therapy. Exclusion criteria included any hepatic disease, renal disease (plasma creatinine >1.5 mg/dl), cigarette smoking, alcohol intake, arterial hypertension (blood pressure >130/85 mmHg), hypercholesterolemia (total cholesterol >250 mg/dl), hypertrgliceridemia (triglyceride >200 mg/dl), or the presence of micro- or macrovascular complications. Microangiopathy was excluded by an ophtalmologic exam of the retina and by at least three determinations of albuminuria excretion rate. Macroangiopathy was excluded by the palpation of peripheral pulses, ankle brachial pressure ratio, and echocolordoppler ultrasound of the carotid arteries. Diabetic patients were not taking any drugs. They were on a standard diet containing at least 50% of calories as carbohydrates. Before, to include a patient in this study, he or she underwent (in chronological order) stress perfusion imaging with technetium during exercise and dipyridamole echocardiography. The negativity of these diagnostic procedures allowed exclusion of subjects with the presence of obstructive coronary artery disease. Twenty healthy subjects were recruited as the control group. They were nonsmokers and had no evidence of present or past hypertension, hyperlipidemia, diabetes, coronary artery disease, or any systemic conditions. All control subjects were following ad libitum diets, had no recent change in body weight, and were taking no medication. The study protocol was approved by the ethics committee of the University of Padua. Both healthy subjects and diabetic patients gave informed consent before being tested. The clinical characteristics of the study populations are reported in Table 1.


View this table:
[in this window]
[in a new window]
  		Table 1— Study population characteristics at baseline, in fasting state

 
Study design
This study was conducted according to a randomized, three-way, cross-over design. There were 3 study days (separated by a 5- to 10-day interval). Patients were on their own diet regimen, and no medication for glycemic control was used between visits. During these 3 study days, the following three therapeutic regimens were adopted in a random order: 1) regular insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark) injected subcutaneously in the periumbelical region 25 min before the standard meal, 2) insulin analog (Novorapid; Novo Nordisk) injected subcutaneously in the periumbelical region immediately before the standard meal, and 3) saline (placebo) injected subcutaneously. Both physicians and patients were blinded to active medications. Blood samples were drawn for obtaining 0-, 1-, and 2-h postprandial glucose, free fatty acids (FFAs), insulin, and lipid levels.

Diabetic patients and control subjects assumed a mixed standardized meal (460 kcal; 54% carbohydrates, 31% lipids, and 25% proteins) (Novasource Novartis). The meals were consumed over a 5-min period under supervision of a nurse. Myocardial perfusion by contrast echocardiography was performed before and 2 h after eating.

Myocardial contrast echocardiography
Myocardial contrast echocardiography (MCE) was performed in apical four- and two-chamber views using intermittent harmonic imaging with a phased-array system (Sonos 5500) interfaced to a S3 transducer that transmits ultrasound at a mean frequency of 1.6 MHz and receives it at 3.2 MHz. The transmit power was set at maximum, and compression was set at 50 dB. Mechanical index was 1.4. Gain settings were optimized at the beginning of each study and were subsequently held constant. Continuous venous infusion of a contrast agent (Levovist; Schering, Berlin, Germany) was performed using an infusion pump (Medrad Pulsar, Indianola, IA). An intensity versus dose curve from the left ventricular cavity was plotted to obtain the dose where the relation was linear. This dose was used in the contrast echocardiographic studies. In each patient, to avoid significant changes in the concentration of contrast in left ventricular cavity before and after the meal only studies with similar values of peak left ventricular cavity contrast intensity (contrast intensity) were analyzed. We accepted a range in peak contrast intensityfasting–to–peak contrast intensitypostprandial ratio from 0.9 to 1.1. Absence of any change in myocardial video intensity over five successive frames by visual assessment indicated the steady state. Once steady state was achieved, repeat imaging was obtained using sequential electrocardiogram triggering at end-systole. The pulsing interval was gated to the electrocardiogram and progressively increased from 80 msec to 10 s. Up to 12 images, acquired at each pulsing interval, were recorded on optical disk for quantitative analysis. Background-subtracted myocardial signal intensity was plotted over the increasing pulsing intervals and fit to an exponential function as described by Wei et al. (9) for the determination of the slope of the ascending curve of myocardial contrast intensity (ß), which provides a measure of myocardial flow velocity, and the myocardial plateau intensity, which correlates to capillary cross-sectional area and hence to myocardial blood volume (MBV). The product (ß x MBV) represents a dimensionless index of myocardial blood flow (MBF). Digitized studies were coded and read by two independent observers blinded to the patient’s identity and the order of the study. An index of mean global myocardial perfusion was calculated by adding the values of regional MBF and dividing this value by the number of analyzed left ventricular segments. In 10 control and 10 diabetic patients in fasting state, repeated measurements for MBV or ß were done to calculate the inter- and intraobserver variability. For this reason we used Pearson’s linear correlations. In this study, the degree of inter- and intraobserver correlations for measurements of MBV (correlation coefficient r = 0.94, linear regression line equation y = 0.852x +1.03, SD of residuals from the line SD = 0.21 and r = 0.96, y = 0.867x + 1.02, SD = 0.20, respectively) and ß (r = 0.94, y = 0.86x + 0.072, SD = 0.023 and r = 0.95, y = 0.88x + 0.071, SD = 0.021, respectively) was acceptable.

Analytical methods
Plasma glucose was measured with the glucose oxidase method on a Beckman Glucose Analyser. Analyses of area under the curve (AUC) was performed by using the trapezoid rule. The total FFA concentration was determined with a microenzymatic technique (coefficient of variation = 6.9 ± 2.3%). Plasma insulin and C-peptide were measured by conventional radioimmunoassay (coefficient of variation = 6 ± 4 and 5.3 ± 3.2%, respectively). Total plasma cholesterol was measured enzymatically with a within-batch precision of 1.57% and a between-batch precision of 2.09%. HDL cholesterol was assayed according to the method of Kostner with a within-batch precision of 1.55% and a between-batch precision of 4.1%. LDL cholesterol was determined with the Friedewald formula: LDL = total cholesterol – HDL cholestrol – triglycerides/5. Triglycerides were assayed by a commercially available kit based on enzymatic method; intra-assay precision was 2.23% and interassay precision 2.78%. A1C was assayed with a chromatographic method.

Statistical analysis
Results are expressed as means ± SD for normally distributed variables. Comparison between fasting and postprandial values and between groups were made with the Student’s t test (paired and unpaired as appropriate). Multiple comparisons were performed with repeated-measure ANOVA, followed by the Fisher protected least significant difference test. Frequencies of a postprandial plasma glucose level ≤120 mg/dl during regular insulin or insulin analog regimen were compared with the {chi}2 test. For all statistical analysis we used the SPSS package version 10.1 for Windows (SPSS, Chicago, IL). A P value ≤0.05 by the two-tailed test was considered to indicate a statistical significance.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
CONCLUSIONS
 References
 
Hemodynamic variables, serum glucose, lipids, FFAs, and insulin
Heart rate and systolic and diastolic blood pressure in fasting state did not differ between diabetic patients and control subjects. Two hours after eating, heart rate and systolic and diastolic blood pressure did not change significantly in either treatment group of diabetic patients (regular insulin, insulin analog, or placebo) or in control subjects. Hence, in type 2 diabetic patients, fasting rate-pressure product was similar to postprandial value independent of experimental conditions (placebo 8,050 ± 1,596, regular insulin 8,020 ± 1,650, insulin analog 8,065 ± 1,674; P = NS for all comparison). In fasting state, type 2 diabetic patients showed higher plasma glucose concentration and A1C content than control subjects. Moreover, total cholesterol, LDL cholesterol, and triglyceride serum levels were higher, while HDL cholesterol levels were lower in diabetic patients than in control subjects (Table 1).

In the placebo study, the postprandial glucose concentrations in type 2 diabetic patients were significantly higher than those in control subjects (223 ± 11 vs. 124 ± 18 mg/dl, P < 0.002). In the studies in which regular insulin or insulin analog were injected, postprandial plasma glucose increased significantly from baseline values, but the peak values were significantly lower than those observed during the placebo study. Percentage changes in glucose values during insulin analog were not statistically different from those observed following regular insulin (116 ± 8 vs. 136 ± 5%, P = NS) (Fig. 1). However, the value of AUC for glucose after regular insulin (20,757 ± 738 mg · dl–1 · 120 min–1) was significantly higher than that observed following insulin analog (18,354 ± 702 mg · dl–1 · 120 min–1, P = 0.032) (Fig. 2). Furthermore, a postprandial plasma glucose concentration ≤120 mg/dl was obtained in 12 of 20 (60%) diabetic patients during insulin analog treatment but in only 6 of 20 (30%) patients during regular insulin regimen (P < 0.01). No significant changes were observed between control subjects and type 2 diabetic patients in insulin levels, FFAs, or triglyceride profiles at any study point (Fig. 1).


Figure 1
View larger version (20K):
[in this window]
[in a new window]
  		Figure 1— Mean ± SE of plasma glucose (left upper panel), plasma insulin (right upper panel), plasma FFAs (left lower panel), and plasma triglyceride (right lower panel) concentration before and after the ingestion of a mixed meal in normal control subjects (•), in type 2 diabetic patients treated with subcutaneous saline injection (placebo study) ({blacksquare}), with regular insulin ({blacktriangleup}), and with insulin analog ({diamondsuit}).

 

Figure 2
View larger version (19K):
[in this window]
[in a new window]
  		Figure 2— AUC for plasma glucose after placebo, insulin analog (IA), or regular insulin (RI) treatment in type 2 diabetic patients.

 
Myocardial perfusion
MCE studies showed that fasting ß, MBV, and MBF did not differ between control subjects and type 2 diabetic patients in the three treatment groups (Table 2). Changes in MBV expression of the capillary cross-sectional area following the mixed meal are shown in Fig. 3. In the postprandial state, ß (0.67 ± 0.24 vs. 0.92 ± 0.25, P < 0.01) and MBV (8.4 ± 2.0 vs. 10.9 ± 1.2, P < 0.01) increased significantly from fasting values in control subjects. As a consequence, postprandial MBF also increased in nondiabetic subjects (5.6 ± 2.0 vs. 9.9 ± 2.8, P < 0.01). In type 2 diabetic patients, during placebo in the postprandial state, ß increased (0.65 ± 0.27 vs. 0.89 ± 0.24, P < 0.01), while MBV (8.34 ± 1.2 vs. 4.3 ± 1.3, P < 0.01) and MBF (5.4 ± 1.5 vs. 3.4 ± 0.9, P < 0.01) reduced significantly in comparison to fasting values. This pattern of postprandial changes in MCE variables did not change significantly after injection of regular insulin before the meal: postprandial ß increased (0.65 ± 0.22 vs. 0.9 ± 0.12, P < 0.01) but MBV (8.2 ± 2 vs. 5.2 ± 1.16, P < 0.01) and MBF (5.4 ± 1.9 vs. 4.2 ± 0.86, P < 0.01) decreased significantly. In type 2 diabetic patients, in whom insulin analog was injected before eating, all MCE variables increased significantly in comparison to fasting values: ß from 0.66 ± 0.18 to 0.9 ± 0.18 (P < 0.01), MBV from 8.2 ± 1.6 to 9.6 ± 1.2 (P < 0.01), and MBV from 5.4 ± 2 to 7.2 ± 1.9 (P < 0.01). Comparisons between type 2 diabetic patients and control subjects show that postprandial ß does not differ, while postprandial MBV and MBF are lower irrespective of treatment. Comparisons between diabetic patients treated with placebo or with different insulin regimens show that the highest postprandial MBV and MBF are obtained after insulin analog injection. Values of postprandial MBV and MBF are higher in diabetic patients after regular insulin injection than those of patients treated with placebo.


View this table:
[in this window]
[in a new window]
  		Table 2— Myocardial contrast echocardiography variables

 

Figure 3
View larger version (58K):
[in this window]
[in a new window]
  		Figure 3— Changes in MBV from fasting to postprandial state in control subjects (Controls) and in type 2 diabetic patients during placebo (DM2-Pl), regular insulin (DM2-RI), and insulin analog (DM2-IA) administration. Comparisons between control subjects and diabetic patients: *P < 0.01. Comparisons between groups of diabetic patients: °P < 0.01 IA compared with placebo and RI, #P < 0.01 RI compared with placebo.

 

   CONCLUSIONS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
References
 
This study demonstrated that insulin analog rather than regular insulin, when administered to type 2 diabetic patients in a controlled mixed meal test setting, improved postprandial glycemic control and has the potential to partially reverse myocardial perfusion abnormalities observed in this metabolic state. In type 2 diabetic patients, a significant decrease in myocardial perfusion, which correlated with hyperglycemia during the postprandial state, has been recently demonstrated (7). This postprandial reduction in myocardial perfusion was determined by a deterioration in function of coronary microvascular circulation as demonstrated by the reduction in myocardial blood volume assessed by MCE. This parameter is related to microvascular indexes (total microvascular density, capillary density, and capillary area) in biopsied myocardial segments (10). The present study confirmed that myocardial perfusion defects due to a microvascular coronary dysfunction occur in the postprandial state in type 2 diabetic patients treated with diet. Similar postprandial myocardial perfusion defects occurred in patients in whom regular insulin was injected but were prevented, together with a better glycemic control, by the injection of insulin analog before the meal.

The occurrence and reversion of myocardial perfusion defects in the postprandial state may recognize a multifactorial pathogenesis. Information from in vitro and in vivo studies have provided biochemical mechanisms by which increases in plasma glucose levels may produce cardiovascular damage. It is accepted that glucose and mixed meals induce oxidative stress with a parallel decreased bioavailability of nitric oxide and an impaired ability to respond to nitric oxide–dependent vasodilatory stimuli (11–13). Besides the production of free radical species, hyperglycemia activates the polyol and glucosamine pathways, increases advanced glycation end product synthesis, and activates protein kinase C (14). A better control of hyperglycemia may reverse this complex metabolic derangement. Moreover, in addition to this action on myocardial substrate metabolism, insulin has a physiological role in vasodilating arterial (15) and venous (16) beds through an increase in nitric oxide synthesis and release. It has been also shown that insulin induces a dose-dependent expression of endothelial nitric oxide synthase in human aortic endothelial cells (17) and stimulates a dose-dependent production of nitric oxide in human umbilical vein endothelial cell (18). Moreover, in human skeletal muscle, it has been shown that insulin induces vasodilation and increases perfusion by a rapid capillary recruitment that is blunted in insulin-resistant states (19). In addition to this vasoactive action in the peripheral vasculature, insulin directly affects myocardial perfusion by enhancing hyperemic myocardial blood flow in a dose-dependent manner (20). Insulin also has other positive effects, most notably the capability to inhibit platelet aggregation by increasing cGMP (21) and an anti-inflammatory and profibrinolytic effect at least in patients with acute myocardial infarction (22).

Postprandial glucose peak (4, 23, 24) is an independent risk factor, especially with respect to CVD. Prevention and delay of late diabetes complications has been shown to be dependent on glycemic control as measured by level of A1C (2, 3). The Diabetes Control and Complications Trial (2) showed that at equivalent levels of A1C, patients on intensive basal-bolus therapy had a reduced risk of complications compared with patients on conventional insulin therapy. This may imply that features of glycemic control not reflected by A1C such as postprandial glycemia may add to or modify the risk of complications. The glycemic control in type 2 diabetic patients occurred only if postprandial glucose control is part of the therapeutic regimen (25), as convincingly shown by Bastyr et al. (26) in the IOEZ study group, in which insulin lispro was used to focus on postprandial blood glucose, resulting in greater impact on overall metabolic control. These observations suggest that control of excessive postprandial glycemia may give clinical benefits in type 2 diabetic patients.

Postprandial abnormalities in myocardial perfusion have been related to peak glucose values (7). In the present study, although insulin analog treatment was associated with peak glucose values not statistically different from those observed following regular insulin, it provided a significant amelioration of postprandial plasma glucose (as indicated by the AUCs) without substantial differences in insulin concentrations. Moreover, a postprandial plasma glucose concentration ≤120 mg/dl was obtained in 60% of diabetic patients during insulin analog treatment but only in 30% of patients during regular insulin regimen.

It should be noted that the small differences in plasma glucose levels may lead to significant changes in vascular response to insulin. This hypothesis stems from the observations made by Capes et al. (27) who showed that small difference in admission plasma glucose levels in patients with acute myocardial infarction but without previously known diabetes are associated with tremendously different outcomes. Furthermore, differences in plasma glucose levels of 20 mg/dl are associated with a twofold increase in cardiogenic shock in patients with acute myocardial infarction (28).

In conclusion, myocardial perfusion defects induced by postprandial hyperglycemia may have relevant clinical implications because, as suggested by the response-to-injury hypothesis (29), they represent an early marker of atherogenic process in the coronary circulation, and their recognition may offer new hope for the early identification of subgroups of patients at increased risk of coronary vessels obstructive disease. Moreover, it may constitute an important goal in the treatment of the disease. The present study offers a practical clinical approach to this relevant problem showing that treatment with insulin analog immediately before eating, by allowing better postprandial glycemic control, either attenuates or reverses the myocardial perfusion defects and coronary microvascular dysfunction in the postprandial state.


   Footnotes
 
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

Received for publication May 25, 2005. Accepted for publication October 14, 2005.


   References
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 

  1. Stamler J, Vaccaro O, Neaton J, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Interventional Trial. Diabetes Care 16:434–434, 1993[Abstract]
  2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853, 1998[Medline]
  3. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977–986, 1993[Abstract/Free Full Text]
  4. Bonora E, Muggeo M: Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 44:2107–2114, 2001[Medline]
  5. DECODE Study Group: Glucose tolerance and cardiovascular mortality: comparison of the fasting and the 2-hour diagnostic criteria. Arch Intern Med 161:397–404, 2001[Abstract/Free Full Text]
  6. Ceriello A: Postprandial hyperglycemia and diabetes complications: is it time to treat (Review)? Diabetes 54:1–7, 2005[Abstract/Free Full Text]
  7. Scognamiglio R, Negut C, Vigili de Kreutzenberg S, Tiengo A, Avogaro A: Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 112:179–184, 2005[Abstract/Free Full Text]
  8. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117, 1995[Medline]
  9. Wei K, Ragosta M, Thorpe J, Coggins M, Moos S, Kaul S: Noninvasive quantification of coronary blood flow reserve in humans using myocardial contrast echocardiography. Circulation 103:2560–2565, 2001[Abstract/Free Full Text]
  10. Shimoni S, Frangogiannis NG, Aggeli CJ, Shan K, Quinones MA, Espada R, Letsou GV, Lawrie GM, Winters WL, Reardon MJ, Zoghbi WA: Microvascular structural correlates of myocardial contrast echocardiography in patients with coronary artery disease and left ventricular dysfunction: implications for the assessment of myocardial hybernation. Circulation 106:950–956, 2002[Abstract/Free Full Text]
  11. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P: Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85:2970–2973, 2000[Abstract/Free Full Text]
  12. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106:1211–1218, 2002[Abstract/Free Full Text]
  13. Aljada A, Ghanim H, Mohanty P, Syed T, Bandyopadhyay A, Dandona P: Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am J Clin Nutr 80:51–57, 2004[Abstract/Free Full Text]
  14. Gerich JE: Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 163:1306–1316, 2003[Abstract/Free Full Text]
  15. Baron AD: Hemodynamic actions of insulin. Am J Physiol 267:E187–E202, 1994
  16. Grover A, Padginton C, Wilson MF, Sung BH, Izzo JL, Dandona P: Insulin attenuates norepinephrine-induced venoconstriction: an ultrasonographic study. Hypertension 25:779–784, 1995[Abstract/Free Full Text]
  17. Aljada A, Dandona P: Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism 49:147–150, 2000[Medline]
  18. Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest 98:894–898, 1996[Medline]
  19. Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, Barett EJ: Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 53:1418–1423, 2004[Abstract/Free Full Text]
  20. Sundell J, Nuutila P, Laine H, Luotolahti M, Kalliokoski K, Raitakari O, Knuuti J: Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow. Diabetes 52:1125–1130, 2002
  21. Trovati M, Massucco P, Mattiello L, Mularoni E, Cavalot F, Anfossi G: Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets: a mechanism involved in the insulin anti-aggregating effect. Diabetes 43:1015–1019, 1994[Abstract]
  22. Chaudhuri A, Janicke D, Wilson MF, Tripathy D, Garg R, Bandyopadhyay A, Calieri J, Hoffmeyer D, Syed T, Ghanim H, Aljada A, Dandona P: Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 109:849–854, 2004[Abstract/Free Full Text]
  23. Barrett-Conner E, Ferrara A: Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study. Diabetes Care 21:1236–1239, 1998[Abstract]
  24. Shaw J, Hodge A, de Courten M, Chitson P, Zimmet P: Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42:1050–1054, 1999[Medline]
  25. Abraira C, McGiure DK: Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans Affairs (VA CSDM) feasibility trial. Am Heart J 138:360–365, 1999
  26. Bastyr EJ 3rd, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE: Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c: IOEZ Study Group. Diabetes Care 23:1236–1241, 2000[Abstract/Free Full Text]
  27. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355:773–778, 2000[Medline]
  28. Zellera M, Cottina Y, Brindisib MC, Dentanc G, Laurentd Y, Janin-Manificate L, L’Huilliera I, Beera JC, Touzerya C, Makkif H, Vergesb B, Wolfa JE, the RICO survey working group: Impaired fasting glucose and cardiogenic shock in patients with acute myocardial infarction. Eur Heart J 25:308–312, 2004[Abstract/Free Full Text]
  29. Janardhanan R, Senior R: Accuracy of dipyridamole myocardial contrast echocardiography for the detection of residual stenosis of the infarct-related artery and multivessel disease early after acute myocardial infarction. J Am Coll Cardiol 43:2247–2252, 2004[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
C. Hohberg, T. Forst, M. Larbig, M. Safinowski, S. Diessel, S. Hehenwarter, M. M. Weber, T. Schondorf, and A. Pfutzner
Effect of Insulin Glulisine on Microvascular Blood Flow and Endothelial Function in the Postprandial State
Diabetes Care, May 1, 2008; 31(5): 1021 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Deedwania, M. Kosiborod, E. Barrett, A. Ceriello, W. Isley, T. Mazzone, and P. Raskin
Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism
Circulation, March 25, 2008; 117(12): 1610 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Kosiborod, S. E. Inzucchi, H. M. Krumholz, L. Xiao, P. G. Jones, S. Fiske, F. A. Masoudi, S. P. Marso, and J. A. Spertus
Glucometrics in Patients Hospitalized With Acute Myocardial Infarction: Defining the Optimal Outcomes-Based Measure of Risk
Circulation, February 26, 2008; 117(8): 1018 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
D. Giugliano, A. Ceriello, and K. Esposito
Glucose metabolism and hyperglycemia
Am. J. Clinical Nutrition, January 1, 2008; 87(1): 217S - 222S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
Z. Liu
Insulin at physiological concentrations increases microvascular perfusion in human myocardium
Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1250 - E1255.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. A. Cooper, A. Whaley-Connell, J. Habibi, Y. Wei, G. Lastra, C. Manrique, S. Stas, and J. R. Sowers
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2009 - H2023.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon
Cardiovascular Actions of Insulin
Endocr. Rev., August 1, 2007; 28(5): 463 - 491.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scognamiglio, R.
Right arrow Articles by Avogaro, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scognamiglio, R.
Right arrow Articles by Avogaro, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum